A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.

Patino LR, Strawn JR, Adler CM, Blom TJ, Welge JA, DelBello MP

Journal of affective disorders7 Apr 2025Cited by 8 (Europe PMC)

PMID40203970DOI10.1016/j.jad.2025.04.046PepBankPUB-40203970

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults treated with olanzapine, mood symptom changes showed no clinically meaningful difference between exenatide and placebo.
In plain wordsIn adults taking olanzapine, mood symptom changes showed no clinically meaningful difference between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMood symptoms
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
There were no clinically meaningful differences between the groups in changes to mood or psychotic symptoms.
3 context sentences(design, population, supporting numbers)
Summary · context
A secondary objective was to evaluate the tolerability of exenatide and its effects on mood and psychotic symptoms.
Summary · context
To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine.
Summary · context
Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks.
Report a problemFND-4020397004
02HumanRandomized controlled trialEfficacy outcome
In adults treated with olanzapine, psychotic symptom changes showed no clinically meaningful difference between exenatide and placebo.
In plain wordsIn adults taking olanzapine, psychotic symptom changes showed no clinically meaningful difference between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changePsychotic symptoms
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Psychiatric symptoms · Mental health and mood
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
There were no clinically meaningful differences between the groups in changes to mood or psychotic symptoms.
3 context sentences(design, population, supporting numbers)
Summary · context
A secondary objective was to evaluate the tolerability of exenatide and its effects on mood and psychotic symptoms.
Summary · context
To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine.
Summary · context
Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks.
Report a problemFND-4020397005
03HumanRandomized controlled trialEfficacy outcome
In overweight or obese adults treated with olanzapine, exenatide produced minor weight loss while placebo produced weight gain.
In plain wordsIn overweight or obese adults taking olanzapine, exenatide caused minor weight loss while placebo caused weight gain.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
Weight change
−0.5 kg
exenatide
Weight change
−0.6%
exenatide
Weight change
2.6 kg
placebo
Weight change
2.8%
placebo
Source sentences
Summary
Participants in the exenatide group experienced on average a minor weight loss, while participants in the placebo group on average experienced weight gain (-0.5 kg [-0.6 %] vs. +2.6 kg [+2.8 %], both p < .01).
3 context sentences(design, population, supporting numbers)
Summary · context
A significant difference in weight change was detected between the treatment groups.
Summary · context
To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine.
Summary · context
Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks.
Report a problemFND-4020397001
04HumanRandomized controlled trialSafety outcome
In adults treated with olanzapine, gastrointestinal symptoms were among the most common side effects with exenatide.
In plain wordsIn adults taking olanzapine, stomach and bowel symptoms were among the most common side effects with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableGastrointestinal symptoms
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
The most common side effects in the exenatide group were gastrointestinal symptoms and headaches.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine.
Summary · context
Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks.
Report a problemFND-4020397002
05HumanRandomized controlled trialSafety outcome
In adults treated with olanzapine, headaches were among the most common side effects with exenatide.
In plain wordsIn adults taking olanzapine, headaches were among the most common side effects with exenatide.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHeadaches
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
The most common side effects in the exenatide group were gastrointestinal symptoms and headaches.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine.
Summary · context
Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks.
Report a problemFND-4020397003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00845507

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

University of Cincinnatin = 54Dec 2008 to Jul 2015

Weight Gain

Trial page ClinicalTrials.govUpdated 20 Apr 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.